{"id":33428,"date":"2012-12-08T14:00:51","date_gmt":"2012-12-08T19:00:51","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=33428"},"modified":"2012-12-08T15:30:39","modified_gmt":"2012-12-08T20:30:39","slug":"prolonged-anticoagulation-with-apixaban-beneficial-in-venous-thromboembolism","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2012\/12\/08\/prolonged-anticoagulation-with-apixaban-beneficial-in-venous-thromboembolism\/","title":{"rendered":"Prolonged Anticoagulation with Apixaban Beneficial in Venous Thromboembolism"},"content":{"rendered":"<p>A new study suggests that extending anticoagulant therapy for an additional year may be beneficial after patients with venous thromboembolism complete their initial course of therapy. The results of AMPLIFY-EXT (Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy-Extended Treatment) were\u00a0<a href=\"https:\/\/ash.confex.com\/ash\/2012\/webprogram\/Paper55483.html\">presented at the annual meeting of the American Society of Hematology meeting\u00a0<\/a>in Atlanta and <a title=\"AMPLIFY-EXT_NEJM\" href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1207541\" target=\"_blank\">published simultaneously in the\u00a0<em>New England Journal of \u00a0Medicine<\/em><\/a>.<\/p>\n<p>After completing a standard anticoagulation regimen for 6 to 12 months, 2486 VTE patients were randomized to either placebo or apixaban (2.5 or 5 mg twice daily) for an additional 12 months.\u00a0At both doses, apixaban treatment was associated with a large reduction in clinical events and no increase in major bleeding events.<\/p>\n<p>The primary endpoint, the composite of death or symptomatic recurrent VTE, was significantly lower in the low-dose and high-dose apixaban groups (3.8% and 4.2%, respectively) than in the placebo group (11.6%).<\/p>\n<p>Very few major bleeding events occurred: 4 (0.5%) in the placebo group, 2 (0.2%) in the low-dose apixaban group, and 1 (0.1%) in the high-dose apixaban group. Clinically relevant nonmajor bleeds occurred in 2.3% of the placebo group, 3.0% of the low-dose apixaban group, and 4.2% of the high-dose apixaban group.<\/p>\n<p>The investigators concluded that the results of the study &#8220;provide a rationale for continuing anticoagulation therapy&#8221; in VTE patients for whom there is uncertainty about the worth of continued anticoagulant therapy. They calculated that 14 patients would need to be treated to prevent one VTE case.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new study suggests that extending anticoagulant therapy for an additional year may be beneficial after patients with venous thromboembolism complete their initial course of therapy. The results of AMPLIFY-EXT (Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy-Extended Treatment) were\u00a0presented at the annual meeting of the American Society [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[495,7],"tags":[492,363,1585,596,747],"class_list":["post-33428","post","type-post","status-publish","format-standard","hentry","category-anticoagulation-2","category-prevention","tag-anticoagulation","tag-apixaban","tag-deep-vein-thrombosis","tag-pulmonary-embolism","tag-venous-thromboembolism"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/33428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=33428"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/33428\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=33428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=33428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=33428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}